演題詳細

一般口演 / Oral Session

一般口演 7 (Oral Session 7) :MDS:臨床 1

print

日程
2013年10月11日(金)
時間
09:30 - 10:30
会場
第6会場 / Room No.6 (ロイトン札幌 2F エンプレス)
座長・司会
南谷 泰仁 (Yasuhito Nannya):1
1:東京大学 血液・腫瘍内科
 
前へ戻る

Revised international prognostic scoring system predicts the response of azacitidine to MDS patients

演題番号 : OS-1-32

松原 悦子 (Etsuko Matsubara):1、東 太地 (Taichi Azuma):1、小林 慎治 (Shinji Kobayashi):1、山之内 純 (Jun Yamanouchi):1、成見 弘 (Hiroshi Narumi):1、藤原 弘 (Hiroshi Fujiwara):1、薬師神 芳洋 (Yoshihiro Yakushijin):2、羽藤 高明 (Takaaki Hato):1、安川 正貴 (Masaki Yasukawa):1

1:Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University、2:Department of Clinical Oncology, Ehime University

 

Although azacitidine (AZA) has been reported to induce 50-60% hematological response in MDS patients, the predictive factors for response to AZA treatment remain largely unknown. We examined the relationship between the AZA response and the risk categorized by the recently revised International Prognostic Scoring System (IPSS-R). We retrospectively analyzed 24 MDS patients treated with AZA. Diagnosis was RCMD (n=6), RAEB-1 (n=2), RAEB-2 (n=4) and AML/RAEB-t (n=12). The IPSS-R categories at the onset of AZA were Very low (n=1), Low (n=2), Intermediate (n=3), High (n=5) and Very high (n=13). The response to AZA was evaluated according to the IWG2006 criteria. The median time from diagnosis to administration of AZA was 13.6 months (0-52). The patients received AZA for a median of 4 cycles (1-15). Hematological improvements were obtained in 13 patients (54%); CR in 2, marrow CR in 3, and SD with HI in 8. The IPSS-R categories of patients who had any hematological improvement were Very Low in 100%, Low in 100%, Intermediate in 100%, High in 60%, and Very high in 53.8%, suggesting that a lower risk of IPSS-R results in the better response of AZA. Although we were unable to evaluate the overall survival in each IPSS-R category because of small sample size, we found that the overall survival rate of patients who achieved transfusion independence is 15/15 (100%) while that of patients with transfusion dependence was 3/9 (33%). These results suggest that IPSS-R is a useful tool to predict the AZA response and that achievement of transfusion independence may improve overall survival.

前へ戻る